medigraphic.com
ISSN 0016-3813 (Print)

2015, Number 4

<< Back Next >>

Gac Med Mex 2015; 151 (4)

Diagnosis and treatment approach for necrotizing scleritis (NS): A clinical case

Hernández-Camarena JC, Rodríguez-García A, Valdez-García J

Language: Spanish
References: 16
Page: 525-528
PDF size: 253.15 Kb.


ABSTRACT

Necrotizing scleritis is an immune-mediated ocular inflammatory process, characterized by an area of avascular necrosis and a profound inflammation of the sclera and episclera. Necrotizing scleritis and its association with peripheral ulcerative keratitis –necrotizing sclerokeratitis (NS)– represents a serious threat for vision and eye integrity, evolves very fast if untreated, and its finding suggests the presence of a potentially lethal systemic vasculitic process. The following case is an example of the diagnostic approach and therapeutic scale in a 63-year-old women with necrotizing sclerokeratitis.


REFERENCES

  1. Dubord PJ, Chalmers A. Scleritis and episcleritis: diagnosis and management. In: Focal Points: Clinical Modules for Ophthalmologists. San Francisco: American Academy of Ophthalmology. 1995;13:65-85.

  2. Albini TA, Rao NA, Smith RE. The diagnosis and management of anterior scleritis. Int Ophthalmol Clin 2005;45(2):191-204.

  3. Okhravi N, Odufuwa B, McCluskey P. Scleritis, Major Review. Surv Ophthalmol. 2005;50:351-63.

  4. Sainz de la Maza M, Jabbur NS, Foster CS. Severity of scleritis and episcleritis. Ophthalmology. 1994;101:389-96.

  5. De la Maza M, Foster S. Ocular Characteristics and Disease Associations in Scleritis-Associated Peripheral Keratopathy. Arch Ophthalmol. 2002;120:15-9.

  6. Karamursel E, Thorne J, Qazi F. Evaluation of Patients with Scleritis for Systemic Disease. Ophthalmology. 2004;111:44-53.

  7. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492-513.

  8. Clewes A, Dawson J, Kaye S, et al. Peripheral ulcerative keratitis in rheumatoid arthritis: successful use of intravenous cyclophosphamide and comparison of clinical and serological characteristics. Ann Rheum Dis. 2005;64:961-2.

  9. Albini TA, Rao NA, Smith RE. The diagnosis and management of anterior scleritis. Int Ophthalmol Clin. 2005;45:191-204.

  10. Hernández-Illas M, Tozman E, Fulcher S, et al. Recombinant human tumour necrosis factor receptor Fc fusion protein (Etanercept): experience as a therapy for sight-threatening scleritis and sterile corneal ulceration. Eye Contact Lens. 2004;30:2-5.

  11. Díaz-Valle D, Miguélez Sánchez R, Fernández Espartero M, et al. Treatment of refractory anterior diffuse scleritis with infliximab. Arch Soc Esp Oftalmol. 2004;79:405-8.

  12. Murphy C, Ayliffe WH, Booth A, et al. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology. 2004;111:352-6.

  13. Aeberli D, Oertle S, Mauron H, et al. Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med Wkly. 2002;132:414-22.

  14. Atchia II, Kidd E, Bell RWD. Rheumatoid Arthritis-Associated Necrotizing Scleritis and Peripheral Ulcerative Keratitis Treated Successfully with Infliximab. J Clin Rheumatol. 2006;12:291-3.

  15. Suhler EB, Lim LL, Beardsley RM, et al. Rituximab Therapy for Refractory Scleritis: Results of a Phase I/II Dose-Ranging, Randomized, Clinical Trial. Ophthalmology. 2014;121:1885-91. [Epub ahead of print].

  16. Nguyen QD, Foster CS. Scleral patch graft in the management of necrotizing scleritis. Int Ophthalmol Clin. 1999;39:109-31.




2020     |     www.medigraphic.com